Carl N. Kraus - 15 Oct 2025 Form 4 Insider Report for Aquestive Therapeutics, Inc. (AQST)

Reporting relationship: Chief Medical Officer
Issuer ticker: AQST
Reported as of: 15 Oct 2025
Net transaction value: -$141,904
SEC form: 4
Accepted by SEC: 17 Oct 2025, 14:01:00 UTC
Prior SEC filing: 12 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Lori Braender, as Attorney-In-Fact

Key filing fact

Carl N. Kraus filed Form 4 for Aquestive Therapeutics, Inc. (AQST) on 17 Oct 2025.

Key facts

This page summarizes Carl N. Kraus's Form 4 filing for Aquestive Therapeutics, Inc. (AQST).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 17 Oct 2025, 14:01.

Change

Previous filing in this sequence was filed on 12 Aug 2025.
Current net transaction value: -$141,904.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001946475 Primary reporting owner

Kraus Carl N

Relationship: Chief Medical Officer
Address: C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN
Signature: /s/ Lori Braender, as Attorney-In-Fact
Signature date: 16 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AQST transaction

Common Stock

Sale

Transaction value: $141,904
Shares: -20,272
Change %: -6.7%
Price: $7.00
Shares after: 282,475
Date: 15 Oct 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4.

Footnote F2

The reported transaction involves sale transactions from $7.00 to $7.02 per share. The weighted average price per share was $7.00. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price.